EyePoint, Inc. (EYPT) stock forecast & analysis
0.4400
NasdaqGM · USDDelayed by 15 minutes
Down: -2.5500, -85.3%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.5500
- Previous close
- 2.99
- Day range
- 0.4026 – 0.6000
- 52-week range
- 0.4000 – 19.11
- Volume (shares)
- 183.42M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 86.21M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.68
- Market cap
- 37.93M
Market Scanner’s AI analysis of EyePoint, Inc. (EYPT), updated October 2026: EyePoint Pharmaceuticals (EYPT) faced significant headwinds following disappointing clinical trial results and subsequent workforce reductions.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of EyePoint, Inc. (EYPT) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
EyePoint Pharmaceuticals (EYPT) faced significant headwinds following disappointing clinical trial results and subsequent workforce reductions.
Recent analyses for EYPT covered the company's severe stock price decline, driven by negative topline results from its LUCIA Phase 3 clinical trial for DURAVYU™ in wet AMD. The failure to meet the primary endpoint led to a substantial share price drop, a workforce reduction of 53%, and the early termination of the Phase III trial. Technical indicators presented a strongly bearish outlook, with the stock trading significantly below its 50-day and 200-day SMAs and exhibiting extreme oversold conditions.
EYPT news & sentiment
News coverage highlighted significant negative developments for EyePoint Pharmaceuticals, focusing on disappointing clinical trial results and substantial workforce reductions. Social media sentiment reflected the sharp stock price decline, with discussions centering on the trial setback and its impact on the company's future.
EYPT technical picture
Technical indicators for EYPT presented a strongly bearish outlook, with the stock experiencing a severe decline and trading significantly below its 50-day and 200-day SMAs. Momentum readings from the RSI, MFI, and MACD indicated extreme oversold conditions and weak buying pressure, further reinforced by the price trading below the lower Bollinger Band.
Fundamentals
EYPT reported a substantial year-over-year revenue decrease and negative trailing twelve months earnings per share. The company held significant cash reserves relative to its debt, indicating a strong current and quick ratio.
Factors discussed — risks
- Failure to meet primary endpoint in LUCIA Phase 3 clinical trial for DURAVYU™
- Significant year-over-year revenue decrease of 90.5%
- Stock price decline of over 90% across 7-day, 30-day, and 91-day periods
- Extreme oversold conditions indicated by RSI and MFI
- Price trading below the lower Bollinger Band
- Clinical trial results
- Workforce reduction
- Technical indicators
- Revenue decline
Summary updated .
EYPT technical indicators
Common technical indicators for EYPT, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 4.94 | Price below |
| 10-day exponential moving average | 2.70 | Price below |
| Relative strength index (14-day) | 15.28 | Oversold |
| MACD line (12/26/9) | -0.7496 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 1.83 – 4.57 | Price below the lower band |
Analyses
Recent EYPT.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-20 EYPT.US analysis
Get the verdict — free
Frequently asked questions
- What are the risks for EyePoint, Inc.?
- The company faces significant risks stemming from its failure to meet primary clinical trial endpoints, which has led to substantial revenue declines and a sharp drop in stock price. Technical indicators suggest extreme oversold conditions and bearish momentum, with the stock trading significantly below key moving averages and the lower Bollinger Band.
- Is EyePoint, Inc. bullish or bearish?
- Recent AI analyses of EyePoint, Inc. examined factors on both sides. Discussed risks: The company faces significant risks stemming from its failure to meet primary clinical trial endpoints, which has led to substantial revenue declines and a sharp drop in stock price. Technical indicators suggest extreme oversold conditions and bearish momentum, with the stock trading significantly below key moving averages and the lower Bollinger Band. These are descriptive observations, not a recommendation.
- What is the latest sentiment on EyePoint, Inc.?
- News coverage highlighted significant negative developments for EyePoint Pharmaceuticals, focusing on disappointing clinical trial results and substantial workforce reductions. Social media sentiment reflected the sharp stock price decline, with discussions centering on the trial setback and its impact on the company's future.
- How does Market Scanner analyse EyePoint, Inc.?
- Every analysis of EyePoint, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What are the risks for EyePoint, Inc.?
The company faces significant risks stemming from its failure to meet primary clinical trial endpoints, which has led to substantial revenue declines and a sharp drop in stock price. Technical indicators suggest extreme oversold conditions and bearish momentum, with the stock trading significantly below key moving averages and the lower Bollinger Band.
Is EyePoint, Inc. bullish or bearish?
Recent AI analyses of EyePoint, Inc. examined factors on both sides. Discussed risks: The company faces significant risks stemming from its failure to meet primary clinical trial endpoints, which has led to substantial revenue declines and a sharp drop in stock price. Technical indicators suggest extreme oversold conditions and bearish momentum, with the stock trading significantly below key moving averages and the lower Bollinger Band. These are descriptive observations, not a recommendation.
What is the latest sentiment on EyePoint, Inc.?
News coverage highlighted significant negative developments for EyePoint Pharmaceuticals, focusing on disappointing clinical trial results and substantial workforce reductions. Social media sentiment reflected the sharp stock price decline, with discussions centering on the trial setback and its impact on the company's future.
How does Market Scanner analyse EyePoint, Inc.?
Every analysis of EyePoint, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh EYPT.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.